Bausch Health ehemals VALEANT PHARMA Allergan-Übernahme beflügelt (Seite 326)
eröffnet am 30.04.14 17:10:46 von
neuester Beitrag 10.04.24 21:16:45 von
neuester Beitrag 10.04.24 21:16:45 von
Beiträge: 4.274
ID: 1.193.944
ID: 1.193.944
Aufrufe heute: 19
Gesamt: 390.063
Gesamt: 390.063
Aktive User: 0
ISIN: CA0717341071 · WKN: A2JQ1X · Symbol: BHC
6,7700
USD
-4,24 %
-0,3000 USD
Letzter Kurs 23:05:00 NYSE
Neuigkeiten
14:00 Uhr · Accesswire  |
15.05.24 · Accesswire |
14.05.24 · Accesswire |
09.05.24 · Accesswire |
02.05.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,25 | +63,04 | |
| 0,8000 | +45,45 | |
| 1,0000 | +42,86 | |
| 6,2500 | +24,75 | |
| 15,348 | +19,53 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 114,60 | -13,61 | |
| 23,700 | -19,52 | |
| 28,60 | -24,06 | |
| 1,3500 | -25,62 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ™ (Brodalumab) As The Lowest Priced Injectable biologic psoriasis treatment currently on the market.
http://ih.advfn.com/p.php?pid=nmona&article=74390715&symbol=…
LAVAL, Quebec, April 21, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the company has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month, which is the lowest injectable biologic psoriasis treatment currently on the market. SILIQ will also be included in the company's patient access program to further offer financial support and access to patients. SILIQ, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is the only product that included the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint. The sales and marketing of SILIQ are expected to commence in the U.S. during the second half of 2017.
"The Patient Access and Pricing Committee was constructed to help our company ensure patients have the best possible access to our products. Our goal with SILIQ is to provide outstanding efficacy while being the most affordable injectable biologic for patients with moderate-to-severe plaque psoriasis," said Joseph Papa, Chairman and CEO of Valeant.
In May 2016, Valeant established the PAPC to be responsible for the pricing of the company's drugs. The PAPC ensures that Valeant's pricing, contracting, compliance and reimbursement strategies are consistent and compliant with all relevant laws, regulations and guidance, as well as the company's position on patient-affordable access to medicines. The Company's Board of Directors oversees the committee, which is chaired by Papa and includes a multi-disciplinary team of Valeant employees, including doctors, scientists, and other executives.
SILIQ has a Black Box Warning for risk in patients with a history of suicidal thoughts or behavior. SILIQ was approved with a Risk Evaluation and Mitigation Strategy (REMS) involving a one-time enrollment for physicians and one-time informed consent for patients. The most common adverse reactions were headache, arthralgia, fatigue, oropharyngeal pain, and diarrhea. SILIQ is contraindicated in patients with Crohn's disease. Suicidal ideation and behavior have been reported. Serious infections have occurred therefore caution should be exercised when considering the use of SILIQ in patients with a chronic infection or a history of recurrent infection. Patients should be evaluated for tuberculosis infection prior to initiating treatment.
About SILIQ
In February 2017, the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SILIQ, a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by preventing the binding of several types of IL-17 to the receptor. By blocking IL-17 from activating the receptor, SILIQ prevents the body from receiving signals that may lead to inflammation. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes.
http://ih.advfn.com/p.php?pid=nmona&article=74390715&symbol=…
LAVAL, Quebec, April 21, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), the company has decided to list SILIQ™ (brodalumab) injection, at $3,500 per month, which is the lowest injectable biologic psoriasis treatment currently on the market. SILIQ will also be included in the company's patient access program to further offer financial support and access to patients. SILIQ, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. SILIQ is the only product that included the psoriasis area and severity index (PASI 100) during clinical trials as a primary endpoint. The sales and marketing of SILIQ are expected to commence in the U.S. during the second half of 2017.
"The Patient Access and Pricing Committee was constructed to help our company ensure patients have the best possible access to our products. Our goal with SILIQ is to provide outstanding efficacy while being the most affordable injectable biologic for patients with moderate-to-severe plaque psoriasis," said Joseph Papa, Chairman and CEO of Valeant.
In May 2016, Valeant established the PAPC to be responsible for the pricing of the company's drugs. The PAPC ensures that Valeant's pricing, contracting, compliance and reimbursement strategies are consistent and compliant with all relevant laws, regulations and guidance, as well as the company's position on patient-affordable access to medicines. The Company's Board of Directors oversees the committee, which is chaired by Papa and includes a multi-disciplinary team of Valeant employees, including doctors, scientists, and other executives.
SILIQ has a Black Box Warning for risk in patients with a history of suicidal thoughts or behavior. SILIQ was approved with a Risk Evaluation and Mitigation Strategy (REMS) involving a one-time enrollment for physicians and one-time informed consent for patients. The most common adverse reactions were headache, arthralgia, fatigue, oropharyngeal pain, and diarrhea. SILIQ is contraindicated in patients with Crohn's disease. Suicidal ideation and behavior have been reported. Serious infections have occurred therefore caution should be exercised when considering the use of SILIQ in patients with a chronic infection or a history of recurrent infection. Patients should be evaluated for tuberculosis infection prior to initiating treatment.
About SILIQ
In February 2017, the U.S. Food and Drug Administration (FDA) approved the Biologics License Application (BLA) for SILIQ, a novel human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by preventing the binding of several types of IL-17 to the receptor. By blocking IL-17 from activating the receptor, SILIQ prevents the body from receiving signals that may lead to inflammation. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes.
Es geht weiter mit den "zufälligen" Schnapszahlen.
Winter Sale
Jeder sehnst sich nach dem Frühling. Mit VRX wird es ihn nicht geben. Verkaufen Sie jetzt (retten Sie ihr Geld, ansonsten wird es entwertet).Positionieren Sie Ihre Verkaufsorder an einer deutschen Börse.
Wir helfen gerne.
!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: themenfremder Inhalt
Ich setze mal weiter auf das Prinzip "Osterdelle".
Valeant wurde schwer abgestraft, auch nach den Q4 Zahlen.
Hinzu kommt m.E. die Feriendelle oben drauf, will heißen Shortattacke vor den Ferien. Die Leute setzen einen SL. Runter bis in der letzen Ferienwoche, SL-auslösen, Covern und mit Calls wieder raufziehen, bevor die Urlauber daheim sind und den Fehler zu günstigen Kursen korrigieren können.
Nur so eine Theorie.
Hoffentlich kommt nun der Wiederanstieg auf 12 vor den Zahlen...
Valeant wurde schwer abgestraft, auch nach den Q4 Zahlen.
Hinzu kommt m.E. die Feriendelle oben drauf, will heißen Shortattacke vor den Ferien. Die Leute setzen einen SL. Runter bis in der letzen Ferienwoche, SL-auslösen, Covern und mit Calls wieder raufziehen, bevor die Urlauber daheim sind und den Fehler zu günstigen Kursen korrigieren können.
Nur so eine Theorie.
Hoffentlich kommt nun der Wiederanstieg auf 12 vor den Zahlen...
Trading Spotlight
Valeant Pharmaceuticals Intl Inc (VRX): It Is Time To Be Greedy?
https://www.smarteranalyst.com/2017/04/20/valeant-pharmaceut…
http://www.healio.com/dermatology/pediatric-dermatology/news…
...
Disclosure: Valeant Pharmaceuticals International sponsored the Pediatric Eczema Elective Registry, which was the data source for the study.
...
...
Disclosure: Valeant Pharmaceuticals International sponsored the Pediatric Eczema Elective Registry, which was the data source for the study.
...
Antwort auf Beitrag Nr.: 54.761.842 von marty44 am 19.04.17 19:43:25komplett draußen; macht Eurer Ding(es wird nicht mehr überwacht
Valeant Pharmaceuticals Intl Inc.: Is a Recovery Possible?
http://www.fool.ca/2017/04/19/valeant-pharmaceuticals-intl-i… 
Durchsuchen
14:00 Uhr · Accesswire · Bausch Health Companies |
25.04.24 · wO Chartvergleich · BAVARIA Industries Group Akt |